Degarelix
- Generic Name
- Degarelix
- Brand Names
- Firmagon, Degarelix Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C82H103ClN18O16
- CAS Number
- 214766-78-6
- Unique Ingredient Identifier
- SX0XJI3A11
- Background
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.
- Indication
Degaralix is used for the management of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
A Degarelix Trial in Patients With Prostate Cancer
- First Posted Date
- 2010-11-17
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 288
- Registration Number
- NCT01242748
- Locations
- 🇺🇸
Urology Associates of Dover, PA, Dover, Delaware, United States
🇨🇿Vseobecna fakultni nemocnice v Praze, Praha 2, Praha, Czech Republic
🇫🇮Pohjois-Karjalan keskussairaala, Tampere, Finland
A Study of Degarelix in Taiwanese Patients With Prostate Cancer
- First Posted Date
- 2010-10-14
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 110
- Registration Number
- NCT01220869
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
🇨🇳Chi-Mei Foundation Hospital, Tainan, Taiwan
🇨🇳Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2013-05-22
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 127
- Registration Number
- NCT01215513
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of
🇰🇷Kyoungbuk National University Hospital, Daegu, Korea, Republic of
🇰🇷Yonsei University Health System Gangnam Sevrance, Seoul, Eonguro, Gangnam-gu, Korea, Republic of
Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 157
- Registration Number
- NCT01071915
- Locations
- 🇰🇷
Pusan National University Yangsan Hospital, Mulgeum-eup, Gyungnam, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
A Long Term Safety Study of Degarelix in Patients With Prostate Cancer
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 77
- Registration Number
- NCT00967018
- Locations
- 🇪🇸
Hospital Universitari Vall d´Hebron, Barcelona, Spain
🇫🇷Centre Paul Strauss, Strassbourg, France
🇧🇪Institut Jules Bordet, Bruxelles, Belgium
A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
- Conditions
- Lower Urinary Tract Symptoms (LUTS)
- Interventions
- First Posted Date
- 2009-07-28
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 404
- Registration Number
- NCT00947882
- Locations
- 🇧🇪
UZ Brussel, Brussels, Belgium
🇨🇦Dr Steinhoff Clinical Research, Victoria, British Columbia, Canada
🇨🇿Slezska nemocnice, prospevkova organizace, Urologicke oddeleni, Opava, Czech Republic
A Trial of Degarelix in Patients With Prostate Cancer
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 859
- Registration Number
- NCT00946920
- Locations
- 🇺🇸
Arkansas Urology, Little Rock, Arkansas, United States
🇺🇸Palm Beach Urology Associates, PA, Wellington, Florida, United States
🇧🇪UZ Gent, Gent, Belgium
A Study of Degarelix in Patients With Prostate Cancer
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 409
- Registration Number
- NCT00928434
- Locations
- 🇺🇸
Southeastern Urology Center, PA, Tallahassee, Florida, United States
🇺🇸Chesapeake Urology Associates, Baltimore, Maryland, United States
🇺🇸Urology Associates Research, Englewood, Colorado, United States
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 182
- Registration Number
- NCT00884273
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Ospedali riuniti, Ancona, Italy
🇧🇪Institut Jules Bordet, Bruxelles, Belgium
🇫🇮KYS/kirurgian klin (Kuopio), Kuopio, Finland
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 246
- Registration Number
- NCT00833248
- Locations
- 🇬🇧
Kent Oncology Centre Maidstone Hospital, Maidstone, Kent, United Kingdom
🇫🇷Clinique du Parc, Toulouse, France
🇫🇷Centre de Lutte Contre le Cancer Nantes-Atlantique Centre René Gauducheau, Saint Herblain Cedex, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.